Low DDB2 levels predict a significantly better survival when stratifying tumors by DDB2 expression in all 108 oxaliplatin-treated colon cancer patients irrespectively of TNM (Figure 5A and Supplementary Figure S7c). The gene discussed is DDB2; the disease is colonic neoplasm.